Inovio Pharmaceuticals (INO) Enterprise Value (2010 - 2026)
Inovio Pharmaceuticals (INO) posted Enterprise Value of -$37.7 million for Q1 2026, up 35.6% sequentially from -$58.5 million in Q4 2025, and up 44.88% YoY from -$26.0 million in Q1 2025.
Inovio Pharmaceuticals (INO) Enterprise Value (2010 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Enterprise Value for 17 years, with the latest figure at -$37.7 million in Q1 2026.
- Quarterly Enterprise Value rose 44.88% year-over-year to -$37.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$37.7 million (up 44.88% YoY) and the FY2025 annual result came in at -$58.5 million, up 37.83% from the prior year.
- Enterprise Value rose to -$37.7 million in Q1 2026 per INO's latest filing, from -$58.5 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$37.7 million in Q1 2026 and troughed at -$360.4 million in Q1 2022.
- A 5-year average of -$154.9 million and a median of -$110.4 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value plunged 312.99% in 2022, then soared 56.94% in 2025.
- Over 5 years, Enterprise Value stood at -$253.0 million in 2022, then soared by 42.57% to -$145.3 million in 2023, then jumped by 35.23% to -$94.1 million in 2024, then surged by 37.83% to -$58.5 million in 2025, then jumped by 35.6% to -$37.7 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$37.7 million, -$58.5 million, and -$50.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Inovio Pharmaceuticals | 97.94 Mn | 97.94 Mn | - | -36.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36.67 Mn |
| Mar 31, 2026 | -37.68 Mn |
| Dec 31, 2025 | -58.51 Mn |
| Sep 30, 2025 | -50.80 Mn |
| Jun 30, 2025 | -47.55 Mn |
| Mar 31, 2025 | -68.36 Mn |
| Dec 31, 2024 | -94.11 Mn |
| Sep 30, 2024 | -84.80 Mn |
| Jun 30, 2024 | -110.42 Mn |
| Mar 31, 2024 | -105.61 Mn |
| Dec 31, 2023 | -145.29 Mn |
| Sep 30, 2023 | -167.47 Mn |
| Jun 30, 2023 | -194.93 Mn |
| Mar 31, 2023 | -223.75 Mn |
| Dec 31, 2022 | -253.00 Mn |
| Sep 30, 2022 | -281.88 Mn |
| Jun 30, 2022 | -348.13 Mn |
| Mar 31, 2022 | -360.39 Mn |
| Dec 31, 2021 | -401.31 Mn |
| Sep 30, 2021 | -394.94 Mn |